Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields selectively ablate (remove body tissue surgically) heart tissue in patients with atrial fibrillation (AF).
The 607-patient study compared the efficacy and safety of the FARAPULSE PFA System against standard-of-care ablation – either radiofrequency or cryoablation – for paroxysmal or intermittent AF in patients who had previously been unsuccessfully treated with at least one anti-arrhythmic drug.
The potential FDA approval of Farapulse might bolster Boston Scientific's position in the electrophysiology market, given that it could become ...